IGF-1 LR3 Dosage Guide: Protocols, Half-Life and Cycle Length
IGF-1 LR3 (Long R3 IGF-1) is an 83-amino-acid modified growth factor studied in cells and animals. Its reduced binding to IGF-binding proteins can increase biological activity, but does not establish a long human half-life or a validated daily dose. This guide separates proposed mcg ranges, actual research, concentration math and unresolved safety questions. For the background biology, see the IGF-1 LR3 overview. The laboratory product datasheet describes a cell-culture reagent, not a clinical dosing program.
IGF-1 LR3 Dosage Chart: Quick Reference
This is an evidence check on quoted dosage figures, not a dosing ladder. A first-person online post proposes 20–40 mcg daily in a multi-drug routine. It documents a plan, not a verified result. The sources reviewed do not validate any of these ranges for human muscle gain.
| Quoted amount | Evidence level | Frequency | Cycle interpretation |
|---|---|---|---|
| 20–40 mcg | Online proposed use; not a validated beginner dose | Daily in that proposal; not established by human PK | Proposed 5–6 weeks is not a studied safety limit |
| 50–80 mcg | No validated intermediate tier in the sources reviewed | Not established | No validated duration |
| 100–120 mcg | Not an established upper research band or safe ceiling | Not established | Six weeks is not a proven maximum |
Beginner, Intermediate and Advanced Dosing
Beginner, intermediate and advanced are protocol labels, not demonstrated biological thresholds. We did not identify a human LR3 dose-ranging trial establishing an effective starting amount, an 80 mcg benefit plateau or a safe upper limit. Feeling well during an initial week does not establish the safety of escalation. Reports can help identify questions worth studying, but cannot separate LR3 effects from training, diet, other drugs or uncertain product identity.
Half-Life and Once-Daily Coverage
Lower binding is not the same as slower clearance. In Ballard and colleagues' cell and animal experiments, LR3 had greater biological potency but was removed from plasma more rapidly than native IGF-1. Binding proteins can prolong the time IGF-1 remains in blood. These experiments do not measure a human LR3 half-life. The repeated 20–30-hour figure and steady once-daily receptor coverage are not established by the sources reviewed. Nor is one universal 10–20-minute figure a suitable description of all native IGF-1 conditions. Ipamorelin is a different molecule; its schedule cannot settle LR3 timing.
Reconstitution and Dose Math
For arithmetic only, 1 mg equals 1000 mcg. If that amount is fully dissolved in a final solution volume of 1 mL, the concentration is 1000 mcg/mL. A hypothetical 20 mcg amount occupies 0.02 mL; 40 mcg occupies 0.04 mL. On a U-100 scale those volumes correspond to 2 and 4 units, respectively, not biological IU and not necessarily two or four graduation lines. At a final volume of 2 mL, the concentration is 500 mcg/mL and the same amounts occupy 0.04 and 0.08 mL, or 4 and 8 U-100 units. Other syringe calibrations differ.
Correct math does not establish a suitable solvent, injectable quality, route or beyond-use date. Laboratory formulations and handling instructions are product-specific; do not turn a supplier's cell-culture recipe into a human preparation method. Our peptide storage guide and how to inject peptides cover general concepts, not validation of an LR3 product or protocol.
Timing and Injection Sites
Workout timing and injection-site claims need their own evidence. The sources reviewed do not establish that injecting LR3 into a trained muscle improves local growth, or that pre-workout or post-workout use is superior. They also do not establish a human subcutaneous-versus-intramuscular route recommendation. Neither a cell-culture result nor an assumed half-life answers those questions.
Cycle Length
Four-to-six-week routines are discussed online, including the proposal linked above. The cited Ballard experiment included 14 days of treatment in rats; it does not validate a human cycle. The sources reviewed do not establish when receptor desensitization becomes clinically relevant in LR3 users, or a matching time-off period that restores response. A shorter cycle or equal-length break should not be presented as proven protection from adverse effects.
Side Effects and Safety
Blood-glucose lowering and unwanted tissue growth are biologically relevant concerns. The US mecasermin label documents hypoglycemia, including seizures, and effects such as intracranial hypertension and tonsillar growth. It also reports malignancies while noting that a causal relationship to new cancers is unknown. These are observations for prescribed mecasermin, not measured LR3 event rates. They raise relevant questions without proving the same incidence in LR3 users.
A meal or a small amount of LR3 cannot be assumed to eliminate risk. If exposure is followed by symptoms suggesting low glucose, seek prompt medical assessment and disclose the product and other medicines used. Confusion, seizure or loss of consciousness warrants emergency help; call 911 in the US. Do not give food or drink to someone who cannot swallow safely. See NIDDK's low-glucose guidance for symptom recognition and treatment principles.
Legal and Anti-Doping Status
The 2026 WADA Prohibited List, section S2.3, includes IGF-1 and its analogues in and out of competition for athletes governed by those rules. Separately, research-use labeling is not authorization for human treatment. US-approved mecasermin is a different molecule, used for specified pediatric growth-failure conditions, not approval of LR3 for muscle building. A sport restriction is not a blanket statement about criminal law, and an online sale is not proof that a particular supply arrangement is lawful.
Frequently Asked Questions About IGF-1 LR3
The sources reviewed do not establish a normal human IGF-1 LR3 dose. A first-person online post proposes 20–40 mcg daily, but that is a proposed self-experiment, not a dose-ranging trial. Figures such as 50–80 or 100–120 mcg should not be treated as validated intermediate or advanced tiers, safe ceilings or recommendations.
A human injection frequency cannot be established from the sources reviewed. The often-repeated 20–30-hour half-life is not supported here by human pharmacokinetic measurements. In the cited animal experiments, LR3 cleared from blood faster than native IGF-1 despite greater biological potency; that does not establish once-daily coverage in people.
Preparation depends on the exact product; a cell-culture supplier's instructions are not a human injection recipe. For arithmetic only, 1 mg in a final solution volume of 1 mL is 1000 mcg/mL: 20 mcg occupies 0.02 mL and 40 mcg occupies 0.04 mL. Those correspond to 2 and 4 units on a U-100 scale, not biological IU. The calculation does not establish a suitable solvent, sterility, route, dose or storage life.
The reviewed sources do not establish a human LR3 injection route, optimal workout timing or a muscle-specific growth benefit from local injection. A once-daily routine cannot be justified by an unverified half-life. These are separate questions from how to measure a volume accurately.
Four-to-six-week cycles appear in proposed online routines, but the sources reviewed do not validate that duration in humans. A cited 14-day rat experiment is not a human cycle study. There is no established four-to-six-week desensitization threshold or matching break that has been shown to reset response or make repeated LR3 use safe.
Blood-glucose lowering and unwanted tissue-growth effects are biologically relevant concerns, but reliable human LR3 risk rates are not established by the sources reviewed. Prescribed mecasermin has documented hypoglycemia and other adverse effects; it is a different product, so its incidence figures and meal instructions cannot be transferred to LR3. Confusion, seizure or loss of consciousness requires emergency help.
The 2026 WADA list prohibits IGF-1 and its analogues in and out of competition for athletes subject to its rules. Research-use labeling does not establish authorization for human treatment. Approved mecasermin is not approval of LR3 or a bodybuilding indication; sport eligibility and the legality of a particular supply arrangement are separate questions.